Accuratus Lab Services and its principal owner, Ampersand Capital Partners, have acquired Array BioPharma’s chemistry, manufacturing and controls (CMC) operation. Accuratus, formed in July 2014 when ATS Labs acquired Microtest Labs, provides GMP and GLP analytical and microbial testing services to the medical device and biopharma industries, as well as manufacturers of EPA-regulated consumer products. Array’s CMC operation expands its CDMO services for the pharma industry.
 
The Array CMC operation will be known as Avista Pharma Solutions and housed in a 50,000-sq.-ft. lab facility in Longmont, CO.  Existing Accuratus locations will leverage the expanded capabilities of the Longmont team and facility. Avista will continue to support the CMC services requirements of its former parent Array BioPharma while expanding its business with other clients. 
 
Dr. Tom Burnell, chairman of Accuratus board of directors, said, “The addition of Avista solidifies the commercial development strategy of Accuratus and brings a strong scientific team with demonstrated expertise in process chemistry and new drug manufacturing.” Dr. Burnell added, “The entire Accuratus organization is excited to welcome the Avista team to the organization.”
 
“We are pleased to complete the sale of our CMC operation, which we believe has tremendous growth potential as part of a high quality, independent CDMO business such as Accuratus,” said Ron Squarer, chief executive officer, Array BioPharma. “Array looks forward to continuing to work with the Avista team in support of our clinical development programs, which are critical to our future success as a company.”